EMA Authorised: Imatinib Teva (imatinib) — Teva B.V.

View source ↗

Summary

EMA authorised Imatinib Teva (imatinib) for multiple indications including chronic myeloid leukemia, precursor cell lymphoblastic leukemia-lymphoma, myelodyspla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Dermatofibrosarcoma Protuberans
• Hypereosinophilic Syndrome
• Myelodysplastic Myeloproliferative Diseases
• Precursor Cell Lymphoblastic Leukemia-lymphoma

Drugs mentioned

• Imatinib Teva (imatinib)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Myelodysplastic-Myeloproliferative Diseases;Hypereosinophilic Syndrome;Dermatofibrosarcoma. MAH: Teva B.V.. Decision date: 05/03/2026